Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded... ...

TRENDING: You Don't Have To Dig Far To Cash In On Rare Earths Dow Jones stock Merck (MRK) topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued. Gardasil demand is sliding in China. In total, sales of the human papillomavirus vaccine tumbled 24% to $1.75 billion. That just beat forecasts for $1.72 billion. Excluding China, sales declined just 2%. Merck widely beat third-quarter expectations and raised its 2025 profit guidance. But the company also n ...

Baxter International (NYSE:BAX) Q3 2025 Earnings Call October 30, 2025 08:30 AM ET Speaker5Good morning, ladies and gentlemen, and welcome to Baxter International Inc.'s third quarter 2025 earnings conference call. Your lines will remain in a listen-only mode until the question and answer segment of today's call. At that time, if you have a question, you will need to press STAR and the number one on your touchtone phone. If anyone should require assistance during the conference, please press STAR then zero ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q3 2025 Earnings Call October 30, 2025 08:30 AM ET Speaker3Good morning and welcome to the Amneal Pharmaceuticals third quarter 2025 earnings call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo. Please go ahead.Speaker4Good morning and thank you for joining Amneal Pharmaceuticals third quarter 2025 earnings call. Today we issued a press release reporting Q3 results. The earnings press release and presentation are available at amneal.c ...

需要注意的是，按照世卫组织建议，若要实现消除宫颈癌的目标，需要实现女童90%的疫苗接种率。而对于具体 的接种安排、接种率要求、接种年龄范围、考核标准等，今日发布的通知尚未给出明确规定，而通知中所述的"技 术方案"尚未公布。具体信息可能要到"技术方案"公开发布时才能见分晓。 南都讯记者宋承翰 发自北京10月30日，国家疾控局官网发布《关于将人乳头瘤病毒疫苗纳入国家免疫规划有关工 作事宜的通知》，正式宣布HPV疫苗将在2025年11月10日进入国家免疫规划，满13周岁女孩免费接种2剂次双价 HPV疫苗。 在湖北省妇幼保健院，护士为一名来自武汉的女孩注射国产HPV疫苗。新华社资料图 官方发布的政策解读表示，近年来，中国宫颈癌发病率和死亡率呈现上升趋势，发病年龄也呈现年轻化趋势。接 种人乳头瘤病毒（HPV）疫苗能够有效预防高危型HPV感染，减少宫颈癌等疾病的发生。 HPV疫苗主要有2价、4价、9价三类，其中2价疫苗起到预防宫颈癌的效果，9价等疫苗在此基础上增加了预防生殖 器疣的功效。从预防宫颈癌的角度出发，此次国家免疫规划选择了2价疫苗。目前该疫苗有两家国内厂商生产，分 别是厦门万泰和沃森生物旗下的泽润生物。这两款国 ...

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance. ...

Core Insights - Takeda Pharmaceutical Company Limited reported a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion), with earnings per American Depositary Share (EPADS) of 43 cents, missing analyst expectations of 44 cents [1][2] - Total sales for the quarter were $7.52 billion (1.18 trillion yen), falling short of consensus estimates of $8.08 billion [1][3] Financial Performance - First half 2025 sales decreased by 6.9% (-3.9% at constant currency) to 2.22 trillion yen, while core operating profit dropped 11.2% to 639.2 billion yen [3] - Neuroscience revenue significantly impacted the decline, with second quarter Neuroscience sales falling 33% to 97.5 billion yen [3] - Vaccine sales decreased by 21.1% to 20.2 billion yen, while cancer drug sales increased by 4.3% to 149.1 billion yen [3] Segment Performance - Gastrointestinal sales rose by 2% to 353.5 billion yen, while revenue from rare diseases fell by 2.7% to 184.1 billion yen [4] Outlook - Takeda updated its full-year 2025 outlook, revising core revenue guidance from 4.53 trillion yen to 4.50 trillion yen [5] - The company expects core operating profit of 1.13 trillion yen, down from prior guidance of 1.14 trillion yen, and core earnings of 479 yen, reduced from previous guidance of 485 yen [5] Stock Performance - Following the earnings report, TAK stock was trading 2.25% lower at $13.46 in premarket trading [6]

Core Insights - Eli Lilly's shares increased nearly 4% in premarket trading following the release of third-quarter earnings that surpassed expectations and an upward revision of its annual profit forecast [1] Financial Performance - The pharmaceutical company reported third-quarter earnings that exceeded market expectations [1] - Eli Lilly raised its annual profit forecast, indicating strong financial performance and positive outlook for the remainder of the year [1]

By Mrinalika Roy and Mariam Sunny (Reuters) -Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs helped it breeze past Wall Street's third-quarter earnings expectations. Shares of the world's largest healthcare company by market value jumped over 5% in premarket trading even as investors remain wary of drug price negotiations with the Trump administration. Lilly competes with Novo Nordisk for dominance in the weight-loss drug marke ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation, decided to take control of the company’s board. It vowed a strong emphasis on the critical US market to fuel sales growth for Wegovy, and highlighted the need to move faster on the mass-market channels, reported Reuters. Notably, Americans are now seeking weight-loss drugs, such as Wegovy, not from their do ...